TY  - CONF

T1  - CLINICAL FRACTURE INCIDENCE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) AND RISK-REDUCTION FOLLOWING ADDITION OF ZOLEDRONIC ACID TO ANDROGEN DEPRIVATION THERAPY (ADT) WITH OR WITHOUT DOCETAXEL (DOC): LONG-TERM RESULTS FROM 2 PHASE 3 TRIALS FROM THE STAMPEDE PLATFORM PROTOCOL

JO  - JOURNAL OF UROLOGY

PY  - 2023/01/01

AU  - Jones C

AU  - Sachdeva A

AU  - Murphy L

AU  - Murray M

AU  - Brown L

AU  - McCloskey E

AU  - Brown J

AU  - Attard G

AU  - Parmar M

AU  - James N

AU  - Sydes M et al

ED  - 

VL  - 209

SP  - E129

EP  - E129

Y2  - 2025/03/10

ER  -